IP Library Granted Patent US 8,673,632
Granted Patent B2
US 8,673,632 · App. 12/726,286 · Granted Mar 18, 2014

Modulation of apolipoprotein (a) expression

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,673,632
App. No.
12/726,286
Granted
Mar 18, 2014
Kind
B2
Abstract

Compounds, compositions and methods are provided for modulating the expression of apolipoprotein(a). The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein(a). Methods of using these compounds for modulation of apolipoprotein(a) expression and for diagnosis and treatment of disease associated with expression of apolipoprotein(a) are provided.

Claims (4)

1. A method of inhibiting the expression of apolipoprotein(a) in a cell or tissue comprising contacting said cell or tissue with a compound 15 to 30 nucleobases in length targeted to a nucleic acid molecule encoding apolipoprotein(a) (SEQ ID NO:4), wherein said compound comprises at least 8 consecutive nucleobases of SEQ ID NO:86 and is at least 70% complementary to said nucleic acid molecule encoding apolipoprotein(a), so that expression of apolipoprotein(a) is inhibited.

2. The method of claim 1 , wherein the compound is at least 80%, at least 90%, at least 95% or at least 99% complementary with said nucleic acid molecule encoding apolipoprotein(a).

3. The method of claim 1 , wherein the compound has at least one modified internucleoside linkage, sugar moiety, or nucleobase.

4. The method of claim 1 , wherein the compound has at least one 2′-O-methoxyethyl sugar moiety, phosphorothioate internucleoside linkage or 5-methylcytosine.

Assignments (1)
CHANGE OF NAME Recorded Jun 28, 2017
From: ISIS PHARMACEUTICALS, INC.
To: IONIS PHARMACEUTICALS, INC.
Reel/Frame 043029/0264 →